Antibacterial Activity of combinatorial treatments composed of transition-metal/antibiotics against Mycobacterium tuberculosis
Por:
Montelongo-Peralta L.Z., León-Buitimea A., Palma-Nicolás J.P., Gonzalez-Christen J., Morones-Ramírez J.R.
Publicada:
1 ene 2019
Categoría:
Multidisciplinary
Resumen:
Notwithstanding evidence that tuberculosis (TB) is declining, one of the greatest concerns to public health is the emergence and spread of multi-drug resistant strains of Mycobacterium tuberculosis (MDR-TB). MDR-TB are defined as strains which are resistant to at least isoniazid (INH) and rifampicin, the two most potent TB drugs, and their increasing incidence is a serious concern. Recently, notable efforts have been spent on research to pursue novel treatments against MDR-TB, especially on synergistic drug combinations as they have the potential to improve TB treatment. Our research group has previously reported promising synergistic antimicrobial effects between transition-metal compounds and antibiotics in Gram-negative and Gram-positive bacteria. In this work, we evaluated antimycobacterial activity of transition-metals/antibiotics combinatorial treatments against first-line drug resistant strains of Mycobacterium tuberculosis. Our data showed that INH/AgNO 3 combinatorial treatment had an additive effect (bactericidal activity) in an isoniazid-resistant clinical strain of Mycobacterium tuberculosis. Moreover, in vitro evaluation of cytotoxicity induced by both, the individual tratments of AgNO 3 and INH and the combinatorial treatment of INH/AgNO 3 in murine RAW 264.7 macrophages and human A549 lung cells; showed no toxic effects. Together, this data suggests that the INH/AgNO 3 combinatorial treatment could be used in the development of new strategies to treat resistant strains of Mycobacterium tuberculosis. © 2019, The Author(s).
Filiaciones:
Montelongo-Peralta L.Z.:
Universidad Autónoma de Nuevo León, UANL. Facultad de Ciencias Químicas, Av. Universidad s/n. CD. Universitaria, San Nicolás de los Garza, NL 66455, Mexico
Centro de Investigación en Biotecnología y Nanotecnología, Facultad de Ciencias Químicas, Universidad Autónoma de Nuevo León. Parque de Investigación e Innovación Tecnológica, Km. 10 autopista al Aeropuerto Internacional Mariano Escobedo, Apodaca, Nuevo León 66629, Mexico
León-Buitimea A.:
Universidad Autónoma de Nuevo León, UANL. Facultad de Ciencias Químicas, Av. Universidad s/n. CD. Universitaria, San Nicolás de los Garza, NL 66455, Mexico
Centro de Investigación en Biotecnología y Nanotecnología, Facultad de Ciencias Químicas, Universidad Autónoma de Nuevo León. Parque de Investigación e Innovación Tecnológica, Km. 10 autopista al Aeropuerto Internacional Mariano Escobedo, Apodaca, Nuevo León 66629, Mexico
Palma-Nicolás J.P.:
Centro Regional de Control de Enfermedades Infecciosas, Facultad de Medicina, Universidad Autónoma de Nuevo León, UANL. Av. Madero and Dr. Aguirre Pequeño s/n, Mitras centro, Monterrey, Nuevo León 64460, Mexico
Gonzalez-Christen J.:
Laboratorio de Inmunidad Innata. Facultad de Farmacia. Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, Col. Chamilpa, Cuernavaca, Morelos 62209, Mexico
Morones-Ramírez J.R.:
Universidad Autónoma de Nuevo León, UANL. Facultad de Ciencias Químicas, Av. Universidad s/n. CD. Universitaria, San Nicolás de los Garza, NL 66455, Mexico
Centro de Investigación en Biotecnología y Nanotecnología, Facultad de Ciencias Químicas, Universidad Autónoma de Nuevo León. Parque de Investigación e Innovación Tecnológica, Km. 10 autopista al Aeropuerto Internacional Mariano Escobedo, Apodaca, Nuevo León 66629, Mexico
|